1. Home
  2. ARR vs URGN Comparison

ARR vs URGN Comparison

Compare ARR & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ARMOUR Residential REIT Inc.

ARR

ARMOUR Residential REIT Inc.

N/A

Current Price

$11.96

Market Cap

1.8B

Sector

Real Estate

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$26.12

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARR
URGN
Founded
2008
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.2B
IPO Year
2009
2016

Fundamental Metrics

Financial Performance
Metric
ARR
URGN
Price
$11.96
$26.12
Analyst Decision
Buy
Strong Buy
Analyst Count
6
7
Target Price
$15.56
★ $60.71
AVG Volume (30 Days)
★ 4.6M
1.2M
Earning Date
10-21-2026
11-04-2026
Dividend Yield
★ 24.22%
N/A
EPS Growth
★ 747.06
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $1,128,000.00
Revenue This Year
N/A
$190.44
Revenue Next Year
$18.59
$69.25
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$11.83
$16.50
52 Week High
$19.31
$50.81

Technical Indicators

Market Signals
Indicator
ARR
URGN
Relative Strength Index (RSI) 31.27 27.59
Support Level N/A $23.51
Resistance Level $17.59 $27.76
Average True Range (ATR) 0.35 2.05
MACD 0.01 -0.35
Stochastic Oscillator 25.59 13.91

Price Performance

Historical Comparison
ARR
URGN

About ARR ARMOUR Residential REIT Inc.

ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: